New Molecular Markers in the Diagnosis and Therapy of Acute Myeloid Leukemia 🧬
Acute myeloid leukemia remains one of the most challenging problems in modern hematology. Scientists continue to search for specific biomarkers that will not only more accurately predict the course of the disease but also become targets for targeted therapy. 🔬
A recent study by a group of scientists (Dai et al.) shed light on the role of long non-coding RNA TRAF3IP2-AS1 in the pathogenesis of this malignant neoplasm of hematopoietic tissue.
Key findings of the study:
📈 Molecular Profile Analysis of samples from 132 patients revealed that the expression level of TRAF3IP2-AS1 was significantly elevated in bone marrow and peripheral blood cells in acute myeloid leukemia compared to the control group.
🩺 Diagnostic and Prognostic Value This molecule demonstrates high diagnostic efficacy (AUC value was 0.909). High expression of TRAF3IP2-AS1 correlates with an unfavorable prognosis and is an independent risk factor, allowing its use as a biomarker for patient stratification.
⚙️ Progression Mechanism: miR-186-5p / EP300 axis Researchers deciphered a complex regulatory cascade:
- TRAF3IP2-AS1 acts as a “molecular sponge” for microRNA miR-186-5p.
- Normally, this microRNA should suppress the expression of the EP300 gene, which is involved in cell division processes.
- With an excess of TRAF3IP2-AS1, the microRNA is blocked, leading to hyperactivation of EP300. This stimulates uncontrolled proliferation (multiplication) of blast cells, suppresses their natural apoptosis (programmed cell death), and disrupts cell cycle regulation.
🚫 Therapeutic Potential Experimental reduction of TRAF3IP2-AS1 levels (gene silencing) led to cell cycle arrest in the G1 phase and induced tumor cell death. This confirms that this axis is a promising target for the development of new anti-cancer drugs.
The results of the work open new horizons in understanding the epigenetic regulation of leukemogenesis and emphasize the importance of non-coding RNAs in clinical oncohematology. 📑
Source: Dai J, Yang M, Ruan M, Xia R. LncRNA TRAF3IP2-AS1 Serves as a Potential Biomarker and Drives Acute Myeloid Leukemia Progression via miR-186-5p/EP300 Axis. Journal of Clinical Laboratory Analysis. 2026. Unlock the mysteries of blood and bone marrow



